HC Wainwright & Co. Reiterates Buy on Protara Therapeutics, Maintains $23 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Protara Therapeutics (NASDAQ:TARA) and maintained a $23 price target.
May 06, 2024 | 10:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protara Therapeutics maintains a Buy rating and a $23 price target from HC Wainwright & Co., indicating a positive outlook on the stock.
The reiteration of a Buy rating and a maintained price target of $23 by a reputable analyst like Andrew Fein from HC Wainwright & Co. suggests a strong confidence in Protara Therapeutics' potential for growth. This endorsement is likely to instill positive sentiment among investors, potentially driving up the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100